NDA 021515 · Bausch
Wellbutrin Xl
Bupropion Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Nov 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Aug 28, 2003
Approved uses
2
Original approval plus efficacy supplements
Registered trials
440
96 Phase 3, 24 recruiting
FAERS reports
89,988
46,161 serious, 4,230 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older [ see Warnings and Precautions (5.1) ]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [ see Warnings and Precautions (5.1) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking...
What it is approved for
From the label in effect Feb 10, 2026.
Wellbutrin XL is an aminoketone antidepressant, indicated for: • treatment of major depressive disorder (MDD) ( 1.1 ) • prevention of seasonal affective disorder (SAD) ( 1.2 ) 1.1 Major Depressive Disorder (MDD) Wellbutrin XL ® (bupropion hydrochloride extended-release) tablets is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [ see Clinical Studies (14.1) ]. 1.2 Seasonal Affective Disorder (SAD) Wellbutrin XL is indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). The efficacy of bupropion hydrochloride extended-release tablets in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials in adult outpatients with a history of MDD with an autumn-winter seasonal pattern as defined in the DSM [ see Clinical Studies (14.2) ].
Mechanism: The mechanism of action of bupropion is unknown, as is the case with other antidepressants. However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the reuptake of serotonin.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 12, 2006 Supplement 10 · Efficacy · priority review LabelLetter
- Aug 28, 2003 Original approval · Type 3 - New Dosage Form LabelReviewLetter
2 products under this application
- WELLBUTRIN XL · BUPROPION HYDROCHLORIDE 150MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB3
- WELLBUTRIN XL · BUPROPION HYDROCHLORIDE 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB3
Clinical trials
Interventional ClinicalTrials.gov studies with "Bupropion" as an intervention, any sponsor and status, largest first.
- Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)Pivotal-lookingTerminated
Orexigen Therapeutics, IncIndustry
NCT01601704 · 8,910 participants · Start Jun 2012 · Primary completion Aug 2015
Drug: NB32; PBO · For: Obesity; Overweight
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 224 sites in all
- Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)Pivotal-lookingActive, not recruiting
Currax PharmaceuticalsIndustry
NCT06098079 · 8,600 participants (planned) · Start Jan 3, 2024 · Primary completion Jan 2029
Drug: Naltrexone-Bupropion (NB) Combination; Placebo · For: Obesity
Sites: Birmingham, Alabama; Cullman, Alabama; Mobile, Alabama · 140 sites in all
- Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric DisordersPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01456936 · 8,144 participants · Start Nov 2011 · Primary completion Jan 2015
Drug: Placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Phoenix, Arizona; Encino, California · 156 sites in all
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01574703 · 4,595 participants · Start May 2012 · Primary completion Jul 2015
Drug: placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Encino, California; Escondido, California · 134 sites in all
- ISTAPS: A Stepped Primary Care Smoking Cessation InterventionPivotal-lookingStatus unknown
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaAcademic, hospital or other
NCT00125905 · 3,012 participants · Start Oct 2003
Drug: Nicotine Gum and Patch; Bupropion · For: Smoking Cessation
Sites: Barcelona, Spain
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I TrialPivotal-lookingRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT04604509 · 2,010 participants (planned) · Start Aug 4, 2020 · Primary completion Dec 31, 2028
Drug: Bupropion Hydrochloride Controlled-release; Nicotine Replacement and 1 more · For: Cigarette Smoking-Related Carcinoma
Sites: Houston, Texas
- A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese SubjectsPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00532779 · 1,742 participants · Start Oct 2007 · Primary completion May 2009
Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day; Naltrexone SR 32 mg/Bupropion SR 360 mg /day and 1 more · For: Obesity; Overweight
Sites: Birmingham, Alabama; Fairhope, Alabama; Chandler, Arizona · 34 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective8,670
- nausea7,203
- fatigue6,643
- headache6,487
- depression5,807
- anxiety5,186
- pain4,988
- dizziness4,680
- off label use4,354
- insomnia4,118
- diarrhoea3,370
- rash3,205
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,898 |
| 2005 | 3,945 |
| 2006 | 3,762 |
| 2007 | 2,837 |
| 2008 | 2,449 |
| 2009 | 2,653 |
| 2010 | 2,917 |
| 2011 | 2,829 |
| 2012 | 3,352 |
| 2013 | 2,804 |
| 2014 | 3,128 |
| 2015 | 5,162 |
| 2016 | 5,804 |
| 2017 | 4,618 |
| 2018 | 4,468 |
| 2019 | 5,035 |
| 2020 | 4,644 |
| 2021 | 4,230 |
| 2022 | 4,604 |
| 2023 | 4,291 |
| 2024 | 4,912 |
| 2025 | 4,319 |
| 2026 | 3,326 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Wellbutrin XL (Bupropion HCl)
2024 spending
$81.9M
Beneficiaries
3,395
18,653 claims
Per beneficiary
$24,122
$74.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $74,015,160 |
| 2021 | $75,767,020 |
| 2022 | $76,885,992 |
| 2023 | $77,459,753 |
| 2024 | $81,893,852 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R, Murad MH, Chandar AK, et al. · JAMA 2016 · Research Support, N.I.H., Extramural, Systematic Review
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, et al. · Control Clin Trials 2004 · Clinical Trial, Multicenter Study
- Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).
Iosifescu DV, Jones A, O'Gorman C, et al. · J Clin Psychiatry 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis.
Chan B, Kondo K, Freeman M, et al. · J Gen Intern Med 2019 · Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S.
- Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
Anthenelli RM, Benowitz NL, West R, et al. · Lancet 2016 · Multicenter Study, Randomized Controlled Trial
- Bupropion and Naltrexone in Methamphetamine Use Disorder.
Trivedi MH, Walker R, Ling W, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.